ByteDance has completed a $290 million funding round for Anew Labs, the AI drug-discovery unit it spun out of the TikTok parent company earlier this year, valuing the Shanghai-based business at approximately $1.5 billion in its very first external financing round. ByteDance will retain roughly 56 percent of Anew Labs following the raise, according to Reuters, which cited two sources familiar with the transaction.
From Internal Research Team to Independent Unicorn
Anew Labs traces its roots to an AI-for-Science team ByteDance formed internally back in 2021, built around roughly 50 researchers and led by Liu Kai, a former IDG Capital venture capitalist who brought an investment background to a role focused squarely on applying machine learning to molecular biology. The team operated inside ByteDance for years before the company spun it out as an independent entity in June 2026, transferring its algorithms, technology platform, and existing drug pipeline assets along with roughly 50 core staff to the new company.
That transition, from internal research group to freestanding, externally funded company, instantly made Anew Labs a unicorn on the strength of its very first outside financing round, an unusually fast path to that valuation milestone for a company that hasn’t yet advanced a single drug candidate into clinical trials.
Why ByteDance Spun the Business Out
The rationale behind the spin-off centers on a basic mismatch: AI-driven drug discovery follows an industry logic that looks nothing like ByteDance’s core social media and internet businesses. Drug programs can take years to mature, burn significant cash well before generating any revenue, and require scientists who expect equity-based compensation tied to long, multi-year timelines rather than the faster product cycles that define ByteDance’s other ventures. Spinning Anew Labs out gives the unit a dedicated budget and its own capitalization table, letting it compete for scientific talent on its own terms instead of competing internally against ByteDance’s faster-moving product priorities for resources and attention.
ByteDance isn’t stepping away entirely, though. The company continues to supply Anew Labs with computing infrastructure through its Volcano Engine cloud platform, maintaining a practical link between the two organizations even as Anew now operates with its own external investors, governance, and financial oversight.
What Anew Labs Actually Builds
Anew Labs’ technology centers on a handful of proprietary AI systems: Protenix and AnewFold for biomolecular structure prediction, PXDesign or AnewDesign for protein and antibody design, and AnewMind, a large language model assistant built to support scientific reasoning throughout the drug discovery process. Together, these tools are aimed at three core areas: predicting how biomolecules fold and behave, designing antibodies and other therapeutic molecules with AI assistance, and using AI-driven reasoning to guide the broader drug discovery workflow rather than relying purely on traditional wet-lab trial and error.
The Drug Pipeline Behind the Valuation
Anew Labs has produced a small number of actual drug candidates so far, four in total, with an oral small-molecule program targeting IL-17F, a driver of chronic inflammation the company says has proven difficult for conventional small molecules to hit effectively, currently its most advanced asset, now in lead optimization. Separately, Chris Li, who heads Anew’s biology department, presented an AI-designed IL-17 inhibitor at the American Association of Immunologists’ annual meeting in Boston in April, giving outside researchers a public look at one of the company’s AI-generated drug candidates ahead of this funding round.
A Notable Investor Roster
The round drew a heavyweight group of China-focused investors. HSG, formerly known as Sequoia China, led the round alongside IDG Capital and GL Ventures, the venture arm of Hillhouse Investment, with 5Y Capital serving as co-lead. Gaorong Ventures, Primavera Venture Partners, Boyu Capital, and SBP Group also participated as a strategic investor, alongside the state-backed Shanghai Future Industries Fund, a detail that signals a degree of government-linked interest in the outcome alongside purely commercial venture capital.
Committing $290 million to a company’s very first external funding round, for a business with no drug candidates yet in clinical trials, represents an unusually aggressive bet even by venture capital standards, and reflects real conviction from a set of investors not typically known for speculative, early-stage wagers.
What This Says About AI Drug Discovery Valuations
The $1.5 billion price tag effectively sets a new benchmark for how outside investors are willing to value preclinical-stage AI drug discovery companies, businesses whose core assets are computational models and a handful of early-stage drug candidates rather than approved products or late-stage clinical data. That kind of valuation-based price discovery matters beyond Anew Labs itself: it gives the broader AI-for-Science sector a fresh reference point for how the market currently prices computational drug discovery capability against traditional biotech metrics like clinical trial progress.
Part of a Broader Global AI-Pharma Wave
Anew Labs’ emergence lands amid a broader global wave of AI-driven drug discovery deals. Just this week, Novo signed its own AI-focused collaboration with Orbis Medicines worth up to $1.4 billion to design oral cardiometabolic drugs, while companies like Tempus AI have built entire public-market businesses around the thesis that AI represents healthcare’s single largest untapped technology opportunity. Anew Labs’ spin-off and funding round reflect a parallel but distinct version of that same trend playing out inside a Chinese consumer-technology giant: rather than a pharmaceutical company licensing outside AI capability, ByteDance built its own AI-for-Science team internally and is now spinning it out with independent capital and governance, a different structural path toward the same underlying bet that AI can meaningfully accelerate drug discovery.
What Comes Next
For now, Anew Labs’ billion-dollar valuation rests entirely on the promise of its AI platform and a small early pipeline, not on any clinical success. Its IL-17F program remains in lead optimization, well short of even an initial clinical trial, meaning the real test of whether this funding round’s price tag was justified will play out over years, not months, as the company works to convert its computational drug-design capabilities into actual medicines that make it into human trials.